Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Qiagen (QGEN) has drawn investor attention after recent ...

Qiagen’s outgoing chief executive Thierry Bernard, M.D., told investors the company does not “comment on rumors” as takeover talks swirl around the diagnostics specialist. Buyout speculation has been ...

Qiagen NV (QGEN) reported its fourth-quarter 2025 earnings, aligning with market expectations. The company recorded an earnings per share (EPS) of $0.62, matching the forecast, while revenue reached ...

Qiagen (NYSE:QGEN) has recently attracted attention after a period of mixed short term returns, with a 1 day decline of 0.5% and a 7 day decline of 1.0%, alongside a gain over the past month. For ...

Shares of Qiagen (NYSE: QGEN) this past week returned to trading in the $50 per-share range after three years mostly lumbering between the high $30s and mid $40s. Investors flocked back to the stock ...

German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges. The European molecular ...

Parse Biosciences co-founders are CTO Charles Roco and CEO Alex Rosenberg. (Parse Photo) Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will ...

This story has been updated to include comments from a call with investors held on Wednesday morning. NEW YORK – Qiagen announced Tuesday that it will acquire single-cell sample preparation firm Parse ...

VENLO, Netherlands, & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant ...

Momentum building as QIAGEN prepares for three important new instrument launches in 2025 and 2026: QIAsymphony Connect, QIAsprint and QIAmini QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today ...

Momentum building as QIAGEN prepares for three important new instrument launches in 2025 and 2026: QIAsymphony Connect, QIAsprint and QIAmini VENLO, Netherlands ...